Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Aldeyra Therapeutics' stock plunges 75% as FDA demands more trials for its dry eye drug, reproxalap.

flag Aldeyra Therapeutics' stock fell by 75% after the FDA issued a Complete Response Letter for its dry eye disease drug, reproxalap, citing concerns over trial data. flag The FDA requires additional studies to demonstrate the drug's efficacy. flag The biotech company is now under investigation for potential securities law violations. flag Aldeyra plans to release more trial data in the second quarter and resubmit the drug application later this year.

11 Articles